MX2016015877A - Peptidos como agonistas de oxitocina. - Google Patents
Peptidos como agonistas de oxitocina.Info
- Publication number
- MX2016015877A MX2016015877A MX2016015877A MX2016015877A MX2016015877A MX 2016015877 A MX2016015877 A MX 2016015877A MX 2016015877 A MX2016015877 A MX 2016015877A MX 2016015877 A MX2016015877 A MX 2016015877A MX 2016015877 A MX2016015877 A MX 2016015877A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- cycloalkyl
- hydroxy
- hydrogen
- treatment
- Prior art date
Links
- 102400000050 Oxytocin Human genes 0.000 title 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 101800000989 Oxytocin Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 -(CH2)oNH2 Chemical group 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 102000004279 Oxytocin receptors Human genes 0.000 abstract 1
- 108090000876 Oxytocin receptors Proteins 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de fórmula (I) en donde R1 es hidrógeno, alquilo inferior, -CH2-cicloalquilo o cicloalquilo; R2 es hidrógeno, alquilo inferior, alquilo inferior sustituido con hidroxi, o R1 y R2 pueden formar junto con el átomo de N y C al que están unidos un anillo de pirrolidina opcionalmente sustituido con uno o dos átomos de F o con hidroxi, o puede formar una azetidina o un anillo de piperidina; R3 es hidrógeno, alquilo inferior, alquilo inferior sustituido con hidroxi, -(CH2)oNH2, bencilo opcionalmente sustituido con hidroxi, fenilo, -CH2-cicloalquilo o cicloalquilo; R3' es hidrógeno o alquilo inferior; n es 1; m es 0 o 1; o es 1 a 4; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a sus enantiómeros y/o isómeros ópticos de los mismos. Se ha descubierto que los presentes compuestos son agonistas del receptor de oxitocina para el tratamiento del autismo, el estrés, incluyendo el trastorno de estrés postraumático, la ansiedad, incluyendo trastornos de ansiedad y la depresión, la esquizofrenia, trastornos psiquiátricos y la pérdida de memoria, la abstinencia del alcohol, adicción a las drogas y para el tratamiento del síndrome de Prader-Willi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14171440 | 2014-06-06 | ||
| PCT/EP2015/062314 WO2015185584A1 (en) | 2014-06-06 | 2015-06-03 | Peptides as oxytocin agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016015877A true MX2016015877A (es) | 2017-03-27 |
Family
ID=50932985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015877A MX2016015877A (es) | 2014-06-06 | 2015-06-03 | Peptidos como agonistas de oxitocina. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170081368A1 (es) |
| EP (1) | EP3152225B1 (es) |
| JP (1) | JP6535688B2 (es) |
| KR (1) | KR20170004014A (es) |
| CN (1) | CN106459156A (es) |
| AU (1) | AU2015270564A1 (es) |
| CA (1) | CA2950493A1 (es) |
| CL (1) | CL2016003076A1 (es) |
| CR (1) | CR20160562A (es) |
| EA (1) | EA030296B1 (es) |
| IL (1) | IL248625A0 (es) |
| MX (1) | MX2016015877A (es) |
| PE (1) | PE20170427A1 (es) |
| PH (1) | PH12016502251A1 (es) |
| SG (1) | SG11201610221WA (es) |
| WO (1) | WO2015185584A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2970059T3 (es) | 2014-09-19 | 2024-05-24 | Ferring Bv | Método de tratamiento del síndrome de Prader-Willi |
| US10981955B2 (en) | 2017-08-11 | 2021-04-20 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| US20200093884A1 (en) | 2018-09-20 | 2020-03-26 | Mark C. Manning | Stable intranasal formulations of carbetocin |
| CN113801200B (zh) * | 2021-09-28 | 2023-07-25 | 浙江湃肽生物有限公司 | 一种卡贝缩宫素的制备方法 |
| WO2024044633A2 (en) * | 2022-08-23 | 2024-02-29 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Oxytocin derivatives and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
| KR20070022753A (ko) * | 2004-05-26 | 2007-02-27 | 화이자 인코포레이티드 | 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도 |
| FR2875499B1 (fr) * | 2004-09-20 | 2006-10-27 | Sanofi Aventis Sa | Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique |
| KR101763674B1 (ko) * | 2007-01-22 | 2017-08-01 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| MX2010010743A (es) * | 2008-03-31 | 2010-11-04 | Ferring Bv | Analogos de oxitocina. |
| EP2337783A1 (en) * | 2008-09-23 | 2011-06-29 | F. Hoffmann-La Roche AG | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors |
| JP6026273B2 (ja) * | 2009-05-05 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | イソオキサゾール−ピリダジン誘導体 |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| AU2010302945B2 (en) * | 2009-10-01 | 2015-09-24 | The University Of Sydney | Therapy and prevention of problem drinking |
| US9585935B2 (en) | 2010-07-30 | 2017-03-07 | The Regents Of The University Of California | Intranasal oxytocin treatment to improve schizophrenia |
-
2014
- 2014-06-06 CR CR20160562A patent/CR20160562A/es unknown
-
2015
- 2015-06-03 SG SG11201610221WA patent/SG11201610221WA/en unknown
- 2015-06-03 EA EA201692488A patent/EA030296B1/ru not_active IP Right Cessation
- 2015-06-03 CN CN201580028538.6A patent/CN106459156A/zh active Pending
- 2015-06-03 EP EP15725069.7A patent/EP3152225B1/en not_active Not-in-force
- 2015-06-03 MX MX2016015877A patent/MX2016015877A/es unknown
- 2015-06-03 AU AU2015270564A patent/AU2015270564A1/en not_active Abandoned
- 2015-06-03 WO PCT/EP2015/062314 patent/WO2015185584A1/en not_active Ceased
- 2015-06-03 KR KR1020167036061A patent/KR20170004014A/ko not_active Ceased
- 2015-06-03 CA CA2950493A patent/CA2950493A1/en not_active Abandoned
- 2015-06-03 PE PE2016002273A patent/PE20170427A1/es unknown
- 2015-06-03 JP JP2016571215A patent/JP6535688B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-30 IL IL248625A patent/IL248625A0/en unknown
- 2016-11-11 PH PH12016502251A patent/PH12016502251A1/en unknown
- 2016-11-29 CL CL2016003076A patent/CL2016003076A1/es unknown
- 2016-12-05 US US15/368,902 patent/US20170081368A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2950493A1 (en) | 2015-12-10 |
| CR20160562A (es) | 2017-01-06 |
| PH12016502251A1 (en) | 2017-02-06 |
| KR20170004014A (ko) | 2017-01-10 |
| EA030296B1 (ru) | 2018-07-31 |
| CN106459156A (zh) | 2017-02-22 |
| EA201692488A1 (ru) | 2017-05-31 |
| JP6535688B2 (ja) | 2019-06-26 |
| EP3152225A1 (en) | 2017-04-12 |
| JP2017518313A (ja) | 2017-07-06 |
| AU2015270564A1 (en) | 2016-11-17 |
| EP3152225B1 (en) | 2018-11-14 |
| CL2016003076A1 (es) | 2017-08-11 |
| SG11201610221WA (en) | 2017-01-27 |
| WO2015185584A1 (en) | 2015-12-10 |
| PE20170427A1 (es) | 2017-04-26 |
| IL248625A0 (en) | 2017-01-31 |
| US20170081368A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502251A1 (en) | Peptides as oxytocin agonists | |
| NZ708175A (en) | Peptides as oxytocin agonists | |
| CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
| MX370661B (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
| MX375169B (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona. | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| IN2015DN00957A (es) | ||
| PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| MX2015008830A (es) | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. | |
| PH12016502232A1 (en) | Peptides as oxytocin agonists | |
| AR097721A1 (es) | Derivados de etinilo | |
| PE20181003A1 (es) | Compuestos terapeuticos y sus metodos de uso | |
| CR20190014A (es) | Derivados etinilo | |
| MX374574B (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
| TH171910A (th) | เปบไทด์ที่เป็นออกซีโทซินอะโกนิสต์ | |
| PE20170332A1 (es) | NUEVA ASOCIACION ENTRE LA 8-CICLOPROPIL-3-[2-(3-FLUOROFENIL)ETIL]-7,8-DIHIDR0-3H-[1,3]0XAZIN0[6,5-g][1,2,3]BENZOTRIAZINA-4,9-DIONA Y UN INHIBIDOR DE LA ACETILCOLINESTERASA Y LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
| MA40771B1 (fr) | Forme cristalline de 1-(1-méthyl-1h-pyrazol -4-yl)-n- ((1r,5s,7s) -9-méthyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide | |
| PH12012502339A1 (en) | Amido-tropane derivatives |